Viewing Study NCT04561518

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:40 AM
Ignite Modification Date: 2026-06-25 @ 4:06 AM
Study NCT ID: NCT04561518
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2020-09-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Sponsor: Alnylam Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Transthyretin-Mediated Amyloidosis View
None ATTR Amyloidosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None RNAi therapeutic View
None Transthyretin View
None TTR View
None Amyloidosis View
None Hereditary Transthyretin-mediated (hATTR) Amyloidosis View
None hATTR amyloidosis View
None Hereditary ATTR amyloidosis View
None Wild-type amyloidosis View
None wtATTR amyloidosis View
None ATTRv amyloidosis View
None ATTRwt amyloidosis View
None Polyneuropathy View
None Familial amyloid polyneuropathies View
None ATTR View
None Transthyretin amyloidosis View
None TTR-mediated amyloidosis View
None Polyneuropathies View
None Amyloid neuropathies View
None Amyloid neuropathies, familial View
None Amyloidosis, familial View